AU Patent

AU2015252149B2 — Benzoxazepin PI3K inhibitor compounds and methods of use

Assigned to F Hoffmann La Roche AG · Expires 2017-09-14 · 9y expired

What this patent protects

BENZOXAZEPIN P13K INHIBITOR COMPOUNDS AND METHODS OF USE Abstract The invention relates to benzoxazepin compounds of Formula I z2'z1 0 113 5Z z z including stereoisomers, geometric isomers, tautomers, or pharmaceutically acceptable salts thereof, wherein: Z1 is CR 1 or N; Z 2 is …

USPTO Abstract

BENZOXAZEPIN P13K INHIBITOR COMPOUNDS AND METHODS OF USE Abstract The invention relates to benzoxazepin compounds of Formula I z2'z1 0 113 5Z z z including stereoisomers, geometric isomers, tautomers, or pharmaceutically acceptable salts thereof, wherein: Z1 is CR 1 or N; Z 2 is CR 2 or N; Z3 is CR 3 or N; Z 4 is CR 4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring which compounds have anti-cancer activity, and more specifically, inhibit P13 kinase activity. 70939471 (GHMatters) P89244.AU.1 SHEILAB 6/11/15

Drugs covered by this patent

Patent Metadata

Patent number
AU2015252149B2
Jurisdiction
AU
Classification
—
Expires
2017-09-14
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.